论文部分内容阅读
目的探讨利妥昔单抗联合CHOP治疗B细胞性非霍奇金淋巴瘤的临床疗效。方法 2009年04月至2012年04月期间,我院诊治的60例B细胞性非霍奇金淋巴瘤患者,给予利妥昔单抗联合CHOP方案(环磷酰胺CTX、长春新碱VCR、表阿霉素EPI、强泼尼松PDN)进行治疗,对其临床疗效和不良反应等情况,进行观察。结果 60例B细胞性非霍奇金淋巴瘤患者,经过利妥昔单抗联合CHOP治疗后,有32例完全缓解(53.33%),24例部分缓解(40.00%),3例患者病情稳定(5.0%),有1例患者病情进展(1.67%),治疗的总有效率为93.33%。其中,8例患者出现脱发、恶心、呕吐、骨髓抑制等不良反应。结论对于B细胞性非霍奇金淋巴瘤患者,利妥昔单抗联合CHOP治疗的疗效显著,并且不良反应少,值得临床广泛推广。
Objective To investigate the clinical efficacy of rituximab combined with CHOP in the treatment of B-cell non-Hodgkin’s lymphoma. Methods From April 2009 to April 2012, 60 patients with B-cell non-Hodgkin’s lymphoma who were treated in our hospital were given rituximab combined with CHOP regimen (Cyclophosphamide CTX, Vincristine VCR, Adriamycin EPI, prednisone PDN) for treatment, its clinical efficacy and adverse reactions were observed. Results In 60 patients with B-cell non-Hodgkin’s lymphoma, 32 cases were completely relieved (53.33%), 24 partially relieved (40.00%) and 3 patients were stable after rituximab combined with CHOP 5.0%). One patient developed disease (1.67%) and the total effective rate was 93.33%. Among them, 8 cases of patients with hair loss, nausea, vomiting, bone marrow suppression and other adverse reactions. Conclusion For patients with B-cell non-Hodgkin’s lymphoma, rituximab combined with CHOP has significant curative effect and few adverse reactions, which deserves wide clinical application.